Abstract
The general view on cysteine cathepsins, which were long believed to be primarily involved in intracellular protein turnover, has dramatically changed in last 10 to 15 years. The discovery of new cathepsins, such as cathepsins K, V, X, F and O, and their tissue distribution suggested that at least some of them are involved in very specific cellular processes. Moreover, gene ablation experiments revealed that cathepsins play a vital role in numerous physiological processes, such as antigen processing and presentation, bone remodelling, prohormone processing and wound healing. Their involvement in several pathologies, including osteoporosis, rheumatoid arthritis, osteoarthritis, bronchial asthma and cancer have also been confirmed and today several of them have been validated as relevant targets for therapies. Compounds targeting cathepsins S and K are already in clinical evaluation, whereas others are in experimental phases. The cathepsin K inhibitor AAE-581 (balicatib) as the most advanced of them passed Phase II clinical trials in 2005. In this review, we discuss the current view on cathepsins as an emerging group of targets for several diseases and the development of cathepsin K and S inhibitors for treatment of osteoporosis and various immune disorders.
Keywords: Carboxypeptidases cathepsins B, Apoptosis, cancer biology, Tumour Angiogenesis, extracellular matrix (ECM), MHC Class II Antigen
Current Pharmaceutical Design
Title: Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets
Volume: 13 Issue: 4
Author(s): Olga Vasiljeva, Thomas Reinheckel, Christoph Peters, Dusan Turk, Vito Turk and Boris Turk
Affiliation:
Keywords: Carboxypeptidases cathepsins B, Apoptosis, cancer biology, Tumour Angiogenesis, extracellular matrix (ECM), MHC Class II Antigen
Abstract: The general view on cysteine cathepsins, which were long believed to be primarily involved in intracellular protein turnover, has dramatically changed in last 10 to 15 years. The discovery of new cathepsins, such as cathepsins K, V, X, F and O, and their tissue distribution suggested that at least some of them are involved in very specific cellular processes. Moreover, gene ablation experiments revealed that cathepsins play a vital role in numerous physiological processes, such as antigen processing and presentation, bone remodelling, prohormone processing and wound healing. Their involvement in several pathologies, including osteoporosis, rheumatoid arthritis, osteoarthritis, bronchial asthma and cancer have also been confirmed and today several of them have been validated as relevant targets for therapies. Compounds targeting cathepsins S and K are already in clinical evaluation, whereas others are in experimental phases. The cathepsin K inhibitor AAE-581 (balicatib) as the most advanced of them passed Phase II clinical trials in 2005. In this review, we discuss the current view on cathepsins as an emerging group of targets for several diseases and the development of cathepsin K and S inhibitors for treatment of osteoporosis and various immune disorders.
Export Options
About this article
Cite this article as:
Vasiljeva Olga, Reinheckel Thomas, Peters Christoph, Turk Dusan, Turk Vito and Turk Boris, Emerging Roles of Cysteine Cathepsins in Disease and their Potential as Drug Targets, Current Pharmaceutical Design 2007; 13 (4) . https://dx.doi.org/10.2174/138161207780162962
DOI https://dx.doi.org/10.2174/138161207780162962 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Nutrigenomic Analysis of Diet-Gene Interactions on Functional Supplements for Weight Management
Current Genomics Complex Inheritance for Susceptibility to Sudden Cardiac Death
Current Pharmaceutical Design Genomic and Non-genomic Effects of Aldosterone
Current Signal Transduction Therapy Cell Based Approaches for Myocardial Regeneration and Artificial Myocardium
Current Stem Cell Research & Therapy Mending a Broken Heart: Bioengineered Patches and Scaffolds for Cardiac Repair
Recent Patents on Biomedical Engineering (Discontinued) Protein Kinase C Isozyme Selective Peptides - A Current View of What they Tell Us About Location and Function of Isozymes in the Heart
Current Pharmaceutical Design Stiff Left Atrial Syndrome; Prospects and Possibilities. Retrospective Analysis and Review of the Literature
Current Hypertension Reviews Gene-Wide Approach: New Frontiers in Cardiovascular Genetic Epidemiology
Current Hypertension Reviews Therapeutic Application of Endothelial Progenitor Cells for Treatment of Cardiovascular Diseases
Current Stem Cell Research & Therapy Statins and Vulnerable Plaque
Current Pharmaceutical Design The Cardiovascular and Cardiac Actions of Ecstasy and its Metabolites
Current Pharmaceutical Biotechnology Natriuretic Peptide Family: New Aspects
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Steatohepatitis in HIV-Infected Subjects: Pathogenesis, Clinical Impact and Implications in Clinical Management
Current HIV Research Investigational Positive Inotropic Agents for Acute Heart Failure
Cardiovascular & Hematological Disorders-Drug Targets Endothelial (Dys)Function in Lone Atrial Fibrillation
Current Pharmaceutical Design Rheumatoid Arthritis: An Autoimmune Disease with Female Preponderance and Cardiovascular Risk Equivalent to Diabetes Mellitus: Role of Cardiovascular Magnetic Resonance
Inflammation & Allergy - Drug Targets (Discontinued) Antidiabetic Potential of Naturally Occurring Sesquiterpenes: A Review
Current Topics in Medicinal Chemistry The GH/IGF-1 Axis in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets Reduction of Sympathetic Hyperactivity by Agents that Inhibit the Renin Angiotensin Aldosterone System
Current Hypertension Reviews Targeting Cyclooxygenase and Nitric Oxide Pathway Cross-Talk: A New Signal Transduction Pathway for Developing More Effective Anti- Inflammatory Drugs
Current Signal Transduction Therapy